Organisation paid for research Program year 2025 Source: CMS Open Payments

Allergy Partners Austin

Neither a doctor nor a teaching hospital

Research payments

$334,578

41 payments

Through program year 2025, Allergy Partners Austin is reported as receiving $334,578 in research payments, across 41 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$77,480	4
2024	Research	$50,512	4
2023	Research	$103,950	4
2021	Research	$102,635	29

Breakdown

Who paid Research payments · program years 2021–2025

AstraZeneca Pharmaceuticals LP $231,942 12 payments
AbbVie, Inc. $102,635 29 payments

Studies the money was for Research payments · program years 2021–2025

A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $98,963 5 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $91,659 16 payments
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma $90,815 5 payments
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL $42,164 2 payments
A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib For the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046 $9,817 10 payments
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis $1,159 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.